Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Cystic Fibrosis
Interventions: Vancomycin hydrochloride inhalation powder, Placebo inhalation powder; Drug
Lead sponsor: Savara Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 38
States / cities: Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 32 more

Conditions: COVID-19
Interventions: Aerobic Exercise Training, Education; Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Urinary Incontinence
Interventions: Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 95
States / cities: Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 92 more

Conditions: Venous Thromboembolism
Interventions: Enoxaparin; Drug
Lead sponsor: Hamilton Health Sciences Corporation; Other
Eligibility: Up to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Familial Amyotrophic Lateral Sclerosis
Interventions: ISIS 333611; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Baltimore, Maryland • Charlestown, Massachusetts • St Louis, Missouri + 1 more

Conditions: Anemia
Interventions: Vadadustat, Darbepoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 39
States / cities: Chula Vista, California • Granada Hills, California • Los Angeles, California + 31 more

Conditions: HIV Infections, Cytopenias
Interventions: Epoetin alfa; Drug
Lead sponsor: Ortho Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Rosacea
Interventions: CGB-400, Vehicle Gel; Drug
Lead sponsor: CAGE Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Fremont, California

Conditions: Hepatitis B, HBV
Interventions: Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Phoenix, Arizona • Costa Mesa, California • San Diego, California + 10 more

Conditions: Cardiovascular (CV) Risk, Exercise
Interventions: Experimental group using BumptUp mobile exercise app; Behavioral
Lead sponsor: Old Dominion University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Knee Injury
Interventions: J-Tip, Syringe and 25 gauge needle; Device
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 11 Years to 17 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Onychomycosis
Interventions: SUBA-itraconazole, Itraconazole, Placebo; Drug
Lead sponsor: Halcygen Pharmaceuticals Limited; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 8
States / cities: Altamonte Springs, Florida • Miami, Florida • Boise, Idaho + 5 more

Conditions: HIV Infections
Interventions: Placebo, Aprepitant; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: Placebo, SPD489 (Lisdexamfetamine dimesylate), SPD489; Drug
Lead sponsor: Shire; Industry
Eligibility: 4 Years to 5 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 48
States / cities: Dothan, Alabama • Little Rock, Arkansas • Colton, California + 39 more

Conditions: Healthy, Elderly
Interventions: Lactobacillus rhamnosus GG ATCC 53103 (LGG), Placebo; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 65 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: AMG 282, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Santa Monica, California • Aurora, Colorado • South Miami, Florida + 1 more

Conditions: Congenital Heart Disease
Interventions: Macitentan 10 mg, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 3 more

Conditions: Rheumatoid Arthritis
Interventions: placebo, PRO283698; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 9
States / cities: Anniston, Alabama • Orlando, Florida • Ormond Beach, Florida + 6 more

Conditions: Atopic Dermatitis
Interventions: GIA632, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Fremont, California • Rockville, Maryland • Hoboken, New Jersey

Conditions: Type 2 Diabetes Mellitus
Interventions: HE3286, Placebo; Drug
Lead sponsor: Harbor Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 22
States / cities: Anaheim, California • Beverly Hills, California • Buena Park, California + 17 more

Conditions: Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
Interventions: Enpatoran, Placebo, Standard of care (SoC); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Los Angeles, California • Thousand Oaks, California • Cooper City, Florida + 7 more

Conditions: Generalized Anxiety Disorder
Interventions: Placebo, DT120; Other · Drug
Lead sponsor: Definium Therapeutics US, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more

Conditions: Molybdenum Cofactor Deficiency (MoCD), Rare Autosomal Recessive Disorder, Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)
Interventions: ALXN1101, Placebo; Drug
Lead sponsor: Origin Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Celgosivir hydrochloride; Drug
Lead sponsor: Hoechst Marion Roussel; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 24
States / cities: Mobile, Alabama • Beverly Hills, California • Los Angeles, California + 20 more

Search by objective public record fields.

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)

Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose

Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

The Role of Mobile Apps in Promoting Cardiovascular Health and Motivation to Exercise During Pregnancy

Needleless Jet Injected (J-Tip) Lidocaine in Children Undergoing Regional Anesthesia Prior to Knee Arthroscopy

Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals

Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients